ADRC News

Nathaniel Chin, MD, at his desk with the Wisconsin Public Radio logo on his computer

Dr. Nathaniel Chin Talks about Lecanemab and Dementia Care with WPR

Nathaniel Chin, MD, joined WPR's Central Time and The Morning Show to discuss the FDA's full approval of Leqembi (lecanemab-Irmb) and dementia care.
Dr. Nathaniel Chin works at his office. On the right, the logos for CNN and JAMA Network are featured on the photo of Chin working.

Dr. Chin discusses Alzheimer’s drug donanemab in JAMA and on CNN

Nathaniel Chin, MD, was quoted in an article by CNN highlighting the Phase 3 clinical trial results of donanemab, a monoclonal antibody seeking approval from the U.S. Food and Drug Administration (FDA).
A screenshot of Dr. Maria Mora Pinzon being interviewed on Que Pasa Wisconsin with Telemundo.

Que Pasa Wisconsin: Dr. Maria Mora Pinzon shares information about lecanemab on Telemundo Wisconsin

Maria Mora Pinzon, MD, MS, spoke to Telemundo Wisconsin about the approval of the Alzheimer’s disease treatment Leqembi (lecanemab-Irmb).
Headshots of Dr. Maria Mora Pinzon and Dr. Beth Fields are on the left above the NIA IMPACT Collaboratory logo. On the right half of the graphic is text saying "Drs. Maria Mora Pinzon and Beth Fields Named 2023 NIA IMPACT Faculty Scholars."

Drs. Mora Pinzon and Fields Named 2023 NIA IMPACT Faculty Scholars

Maria Mora Pinzon, MD, MS, FACPM, and Beth Fields, PhD, OTR/L, BCG, have been named 2023 Faculty Scholars with the National Institute on Aging (NIA) IMPACT Collaboratory.
A headshot of Dr. Art Walaszek next to the headline "Art Walaszek, MD, Named Chair of APA Council on Medical Education & Lifelong Learning." Below the text is the American Psychiatric Association (APA) logo.

Dr. Art Walaszek Appointed Chair of APA Council on Medical Education & Lifelong Learning

The council focuses on emerging issues and supports the development of resources and programs for psychiatric education across the United States.
Photo of Dr. Cynthia Carlsson

Dr. Cynthia Carlsson discusses lecanemab and the AHEAD study at UW–Madison

Cynthia Carlsson, MD, MS, spoke to multiple media outlets after the U.S. Food and Drug Administration’s (FDA) full approval of lecanemab was announced. She emphasized the treatment will only be approved for people who are diagnosed with mild cognitive impairment (MCI) or mild dementia and also meet other limited criteria.
Scientific image of beta amyloid plaques

FDA fully approves Alzheimer’s medication Leqembi (lecanemab-irmb)

On July 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb), a therapy for Alzheimer’s disease shown to slow the cognitive decline associated with the disease.
Sterling Johnson, PhD, stands in front of a monitor of several PET and MRI scans. He points at an MRI in the middle of a column of three MRIs.

Wisconsin Registry for Alzheimer’s Prevention (WRAP) Receives $35 million renewal grant from NIH

The renewal grant will enable continued in-depth study into biological indicators of Alzheimer’s disease, expansion of the project to identify other causes of cognitive decline, and enhance the diversity of the cohort through recruitment of people from communities historically underrepresented in research.
A map that closes in to show Milwaukee county

Milwaukee to use Dr. Amy Kind’s research to coordinate lead service line replacement across city

Called the Equity Prioritization Plan, this project will utilize the Area Deprivation Index (ADI) – a tool developed by Dr. Amy Kind’s research team at the Center for Health Disparities Research (CDHR) - as the cornerstone of its metric to identify neighborhoods in greatest need of lead service line replacement.
A group in front of a wayfinding sign pointing to head upstairs for the 2023 Solomon Carter Fuller Brain Health Brunch event

Brain Health Brunch Features Dr. Thomas Karikari, Resources, Music, Soul Food and More

Nearly 200 people attended the Solomon Carter Fuller Brain Health Brunch on April 15, 2023, held at the Sheraton Madison Hotel in Madison, Wisconsin.